Home > Healthcare > Pharmaceuticals > Finished Drug Form > Intravenous Immunoglobulin Market

Intravenous Immunoglobulin Market Share

Report ID: GMI6491
Published Date: Aug 2023
Report Format: PDF

Download Free Sample

Intravenous Immunoglobulin Market Share

Some of the major market players operating in the intravenous immunoglobulin are:

Takeda Pharmaceutical Company Limited
Grifols SA
CSL Behring
ADMA Biologics
Octapharma AG
Baxter International Inc
LFB Biotechnologies
China Biologics Products Inc.
Kedrion Biopharma
Intas Pharmaceuticals

These players focus on strategic partnerships, new product & service launch for market expansion.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Intravenous immunoglobulin (IVIG) industry size was USD 10.9 billion in 2022 and is projected to exhibit 7.6% CAGR from 2023 to 2032 attributed to the high prevalence of primary immunodeficiency disorders and secondary immunodeficiencies worldwide.

The IgG segment is poised to record significant growth through 2032 driven by its remarkable versatility, which encompasses a diverse array of functions within the immune system.

North America held 52.3% share of the IVIG market in 2022 and is anticipated to grow at 7.7% CAGR from 2023 to 2032 owing to the high prevalence of immune-mediated diseases, autoimmune disorders, and primary immunodeficiency diseases.

Some of the major companies in the intravenous immunoglobulin industry are Takeda Pharmaceutical Company Limited., Grifols SA, ADMA Biologics, Octapharma AG, Baxter International Inc., LFB Biotechnologies, China Biologics Products Inc., Kedrion Biopharma, and Intas Pharmaceuticals.